Sarepta Therapeutic Stock Rating Reaffirmed by Robert W. Baird (SRPT)
Sarepta Therapeutic (NASDAQ:SRPT)‘s stock had its “buy” rating reaffirmed by equities research analysts at Robert W. Baird in a research note issued to investors on Thursday, Stock Ratings Network.com reports.
SRPT has been the subject of a number of other recent research reports. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Sarepta Therapeutic (NASDAQ:SRPT) in a research note to investors on Thursday, September 26th. They now have a $65.00 price target on the stock. Separately, analysts at Needham & Company reiterated a “positive” rating on shares of Sarepta Therapeutic (NASDAQ:SRPT) in a research note to investors on Monday, September 23rd. Finally, analysts at Piper Jaffray Cos. upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “neutral” rating to an “overweight” rating in a research note to investors on Friday, September 20th. Six research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $51.46.
Sarepta Therapeutic (NASDAQ:SRPT) opened at 48.03 on Thursday. Sarepta Therapeutic has a 52 week low of $21.21 and a 52 week high of $49.61. The stock has a 50-day moving average of $37.97 and a 200-day moving average of $37.1. The company’s market cap is $1.610 billion.
Sarepta Therapeutic (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.67) by $0.21. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.08 million. Sarepta Therapeutic’s revenue was down 73.2% compared to the same quarter last year. On average, analysts predict that Sarepta Therapeutic will post $-3.24 earnings per share for the current fiscal year.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.